{
  "docId": "019de072-4729-7396-8f8e-eb3955e66e61",
  "docSlug": "7286daabf487d40c2a70ede12061c49a",
  "documentTitle": "Apexigen | SPAC Presentation Deck | 28 slides",
  "authorId": "apexigen",
  "authorName": "Apexigen",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 28,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 20,
  "notes": "The slide highlights a 'Single MoA Focus' on the right, emphasizing the mechanism of action for the combination therapies.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-4729-7396-8f8e-eb3955e66e61/13",
  "deckHref": "/decks/019de072-4729-7396-8f8e-eb3955e66e61",
  "deckJsonHref": "/decks/019de072-4729-7396-8f8e-eb3955e66e61.json",
  "deckAnchorHref": "/decks/019de072-4729-7396-8f8e-eb3955e66e61#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.2,
        "x": 0.77,
        "y": 0.28
      },
      "kind": "callout",
      "text": "Single MoA Focus: Ongoing Phase 2 trials evaluate combination with tumoricidal agents that may cause immunogenic cell death and tumor antigen release",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd77401b-8633-4808-8baf-7362f0c568ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.8,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1 Decision Resources G7 drug treated patients annual incidence... 2 Company-commissioned estimates",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7e1b1a33-309c-4ea3-a62d-e1dc3ae64398",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.7,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "table",
      "text": "Indication, Line of Therapy, Combo Regimen, Catalyst, Addressable Population, Annual Market Potential",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "186a722e-17ce-4030-9688-5513f034c898",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Focused on 5 High Priority Phase 2 Combination Trials",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "216b4b6f-7701-4e66-8677-a9dfbc8163ff",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "969b5348-3fc5-4052-ba0e-96335232cf7d",
      "evidence": "The slide features a table summarizing key information about the company's Phase 2 combination trials.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 15,
      "from": 10,
      "beatId": "eabcce46-c7fe-4e05-b519-ae0aa88c80cb",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "The deck provides details on Sotigalimab's clinical development program and potential applications.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}